Expression of Serum MMP-2 in Patients with Papillary Thyroid Cancer Recurrence or Residuum_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

HUANG Yong , CHENG Ruochuan

Surgical Center of Thyroid， The First Affiliated Hospital of Kunming Medical University， Kunming 650032， Yunnan Province， China;

Corresponding author：

Keywords：

Papillary thyroid cancer; Lymph node metastasis; Recurrence; Residuum; Matrix metalloproteinase-2

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective 　To explore the expression of matrix metalloproteinase （MMP）-2 in patients with papillary thyroid cancer （PTC） recurrence or residuum and its value of clinical application.
Methods 　The serums from 68 patients with thyroid disease underwent operation and 15 health examinations under stomachs empty from March 2009 to December
2009 in this hospital were gathered. Sixty-eight patients with thyroid disease were divided into PTC with lymph node metastasis （LNM） group （n=19），PTC recurrence or residuum with LNM group （n=17），PTC without LNM group （n=10），and benign thyroid disease group （n=22） according to the postoperative pathological findings，15 health examinations as control group. The expression of MMP-2 of serum sample was detected by ELISA method. The difference of the expression of MMP-2 in each group was analyzed.
Results 　The expressions of MMP-2 in the PTC recurrence or residuum with LNM group，PTC with LNM group，PTC without LNM group， benign thyroid disease group，and the control group were （1 724.00±762.24） ng/ml，（1 329.16±776.59） ng/ml，（1 489.61±546.53） ng/ml，（1 264.87±817.27） ng/ml，and （608.43±88.63） ng/ml，respectively. The expressions of MMP-2 in the PTC with LNM group and PTC recurrence or residuum with LNM group were significantly higher than those in the benign thyroid disease group （P＜0.05） and the control group （P＜0.05），respectively，which in the PTC without LNM group was significantly higher than that in the control group （P＜0.05）. There was no significant difference of MMP-2 expression of serum between the benign thyroid disease group and the control group （P＞0.05），which were no significant difference among the other threemalignant disease groups （P＞0.05）. The MMP-2 positive expression rates were 79%，76%，80%，41%，and 20% in the PTC with LNM，PTC recurrence or residue with LNM group，PTC without LNM group，benign thyroid disease group，and control group，respectively. The MMP-2 positive expressions rates of serums were not significantly different among three malignant disease groups （P＞0.05），but which were significantly higher than those of the benign thyroid disease group （P＜0.01） and control group （P＜0.01），respectively.
Conclusions 　The MMP-2 level of serum can be used as an index to judge preoperative thyroid nodules，which can not be use to determine whether PTC metastasis or not.

Citation： HUANG Yong,CHENG Ruochuan,.. Expression of Serum MMP-2 in Patients with Papillary Thyroid Cancer Recurrence or Residuum. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2012, 19(8): 864-867. doi: Copy

1.	江现强，刘志明，赫军，等. MMP-2在甲状腺癌中的表达及其临床意义[J]. 广西医科大学学报， 2005， 22(6)：868-870.
2.	万正东，陆云飞，刘志明. MMP-2、MMP-7在甲状腺乳头状癌中的表达及其临床意义[J]. 广西医科大学学报， 2008， 25(5)：677-679.
3.	Nakamura H， Ueno H， Yamashita K， et al. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas[J]. Cancer Res， 1999， 59(2)：467-473.
4.	Purcell WT， Michelle AR， Manuel H. Development of matrix metalloproteinase inhibitors in cancer therapy[J]. J Natl Cancer Inst， 2002， 16(5)：1189-1227.
5.	周少飞，李扬，丁红光. 血清中MMP-2和MMP-9与乳头状甲状腺癌的关系[J]. 河北医药， 2008， 30(1)：6-7.
6.	Liotta LA， Stetler-Stevenson WG. Tumor invasion and metastasis：an imbalance of positive and negative regulation[J]. Cancer Res， 1991， 51(18 Suppl)：5054s-5059s.
7.	Westermarck J， Kähäri VM. Regulation of matrix metalloproteinase expression in tumor invasion[J]. FASEB J， 1999， 13(8)：781-792.
8.	Shiomi T， Okada Y. MT1-MMP and MMP-7 in invasion and metastasis of human cancers[J]. Cancer Metastasis Rev， 2003， 22(2-3)：145-152.
9.	Visse R， Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinasesl structure， function， and biochemistry[J]. Circ Res， 2003， 92(8)：827-839.
10.	Tayebjee MH， Lim HS， Macfadyen RJ， et al. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and-2 in type 2 diabetes：effect of 1 year’s cardiovascular risk reduction therapy[J]. Diabetes Care， 2004， 27(8)：2049-2051.
11.	Birkedal-Hansen H， Moore WG， Bodden MK， et al. Matrix metalloproteinases：a review[J]. Crit Rev Oral Biol Med， 1993， 4(2)：197-250.
12.	Mackenzie EJ， Mortimer RH. Thyroid nodules：thyroid cancer[J]. The Lancet， 1964， 284(7351)：129-130.
13.	Korem S， Kraiem Z， Shiloni E， et al. Increased expression of matrix metalloproteinase-2：a diagnostic marker but not prognostic marker of papillary thyroid carcinoma[J]. Isr Med Assoc J， 2002， 4(4)：247-251.
14.	Ferlay J， Bray F， Pisani P， et al. Cancer Inc ferlay idence， mortality and prevalence worldwide， 26[M]. lyon：Iarc press， 2005：57-64.
15.	Kahari VM， Saarialho-Kere U. Matrix metalloproteinases and their inhibitors in tumour growth and invasion[J]. Ann Med， 1999， 31(1)：34-45.
16.	Komorowski J， Pasieka Z， Jankiewicz-Wika J， et al. Matrix metalloproteinases， tissue inhibitors of matrix metalloproteinases and angiogenic cytokines in peripheral blood of patients with thyroid cancer[J]. Thyroid， 2002， 12(8)：655-662.
17.	Massova I， Kotra LP， Fridman R， et al. Matrix metalloproteinases：structures， evolution， and diversification[J]. FASEB J， 1998， 12(12)：1075-1095.
18.	Parsons SL， Watson SA， Collins HM， et al. Gelatinase (MMP-2 and -9) expression in gastrointestinal malignancy[J]. Br J Cancer， 1998， 78(11)：1495-1502.
19.	Höyhtyä M， Fridman R， Komarek D， et al. Immunohistochemical localization of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies[J]. Int J Cancer， 1994， 56(4)：500-505.
20.	Maruyama S， Kawata R， Shimada T， et al. Study of matrix metalloproteinase-2 and -9 in thyroid papillary cancer[J]. Nippon Jibiinkoka Gakkai Kaiho， 2000， 103(5)：499-505.
21.	Kraiem Z， Korem S. Matrix metalloproteinases and the thyroid[J]. Thyroid， 2000， 10(12)：1061-1069.
22.	Chambers AF， Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis[J]. J Natl Cancer Inst， 1997， 89(17)：1260-1270.
23.	Pasieka Z， Stepien H， Czyz W， et al. Concentration of metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in theserum of patients with benign and malignant thyroid tumours treated surgically[J]. Endocr Regul， 2004， 38(2)：57-63.
24.	Murphy G， Docherty J. The matrix metalloproteinases and their inhibitors[J]. Am J Resp Cell Mol Biol， 1992， 7(2)：120-125.
25.	Cho Mar K， Eimoto T， Tateyama H， et al. Expression of matrix metalloproteinases in benign and malignant follicular thyroidlesions[J]. Histopathology， 2006， 48(3)：286-294.

1. 江现强，刘志明，赫军，等. MMP-2在甲状腺癌中的表达及其临床意义[J]. 广西医科大学学报， 2005， 22(6)：868-870.
2. 万正东，陆云飞，刘志明. MMP-2、MMP-7在甲状腺乳头状癌中的表达及其临床意义[J]. 广西医科大学学报， 2008， 25(5)：677-679.
3. Nakamura H， Ueno H， Yamashita K， et al. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas[J]. Cancer Res， 1999， 59(2)：467-473.
4. Purcell WT， Michelle AR， Manuel H. Development of matrix metalloproteinase inhibitors in cancer therapy[J]. J Natl Cancer Inst， 2002， 16(5)：1189-1227.
5. 周少飞，李扬，丁红光. 血清中MMP-2和MMP-9与乳头状甲状腺癌的关系[J]. 河北医药， 2008， 30(1)：6-7.
6. Liotta LA， Stetler-Stevenson WG. Tumor invasion and metastasis：an imbalance of positive and negative regulation[J]. Cancer Res， 1991， 51(18 Suppl)：5054s-5059s.
7. Westermarck J， Kähäri VM. Regulation of matrix metalloproteinase expression in tumor invasion[J]. FASEB J， 1999， 13(8)：781-792.
8. Shiomi T， Okada Y. MT1-MMP and MMP-7 in invasion and metastasis of human cancers[J]. Cancer Metastasis Rev， 2003， 22(2-3)：145-152.
9. Visse R， Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinasesl structure， function， and biochemistry[J]. Circ Res， 2003， 92(8)：827-839.
10. Tayebjee MH， Lim HS， Macfadyen RJ， et al. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and-2 in type 2 diabetes：effect of 1 year’s cardiovascular risk reduction therapy[J]. Diabetes Care， 2004， 27(8)：2049-2051.
11. Birkedal-Hansen H， Moore WG， Bodden MK， et al. Matrix metalloproteinases：a review[J]. Crit Rev Oral Biol Med， 1993， 4(2)：197-250.
12. Mackenzie EJ， Mortimer RH. Thyroid nodules：thyroid cancer[J]. The Lancet， 1964， 284(7351)：129-130.
13. Korem S， Kraiem Z， Shiloni E， et al. Increased expression of matrix metalloproteinase-2：a diagnostic marker but not prognostic marker of papillary thyroid carcinoma[J]. Isr Med Assoc J， 2002， 4(4)：247-251.
14. Ferlay J， Bray F， Pisani P， et al. Cancer Inc ferlay idence， mortality and prevalence worldwide， 26[M]. lyon：Iarc press， 2005：57-64.
15. Kahari VM， Saarialho-Kere U. Matrix metalloproteinases and their inhibitors in tumour growth and invasion[J]. Ann Med， 1999， 31(1)：34-45.
16. Komorowski J， Pasieka Z， Jankiewicz-Wika J， et al. Matrix metalloproteinases， tissue inhibitors of matrix metalloproteinases and angiogenic cytokines in peripheral blood of patients with thyroid cancer[J]. Thyroid， 2002， 12(8)：655-662.
17. Massova I， Kotra LP， Fridman R， et al. Matrix metalloproteinases：structures， evolution， and diversification[J]. FASEB J， 1998， 12(12)：1075-1095.
18. Parsons SL， Watson SA， Collins HM， et al. Gelatinase (MMP-2 and -9) expression in gastrointestinal malignancy[J]. Br J Cancer， 1998， 78(11)：1495-1502.
19. Höyhtyä M， Fridman R， Komarek D， et al. Immunohistochemical localization of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies[J]. Int J Cancer， 1994， 56(4)：500-505.
20. Maruyama S， Kawata R， Shimada T， et al. Study of matrix metalloproteinase-2 and -9 in thyroid papillary cancer[J]. Nippon Jibiinkoka Gakkai Kaiho， 2000， 103(5)：499-505.
21. Kraiem Z， Korem S. Matrix metalloproteinases and the thyroid[J]. Thyroid， 2000， 10(12)：1061-1069.
22. Chambers AF， Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis[J]. J Natl Cancer Inst， 1997， 89(17)：1260-1270.
23. Pasieka Z， Stepien H， Czyz W， et al. Concentration of metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in theserum of patients with benign and malignant thyroid tumours treated surgically[J]. Endocr Regul， 2004， 38(2)：57-63.
24. Murphy G， Docherty J. The matrix metalloproteinases and their inhibitors[J]. Am J Resp Cell Mol Biol， 1992， 7(2)：120-125.
25. Cho Mar K， Eimoto T， Tateyama H， et al. Expression of matrix metalloproteinases in benign and malignant follicular thyroidlesions[J]. Histopathology， 2006， 48(3)：286-294.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Expression of Serum MMP-2 in Patients with Papillary Thyroid Cancer Recurrence or Residuum

Abstract Full text Figures/Tables Video References Cited by

Format

Content